A major legal battle is taking shape in 2026 over one of the most widely implanted orthopedic devices in recent years. The Zimmer Biomet CPT Hip lawsuit wave is accelerating rapidly, with individual cases now being filed in courts across all 50 states following a July 2024 recall and a September 2024 FDA safety warning. This week, the Judicial Panel on Multidistrict Litigation held its July 30, 2026 Asheville hearing session — a critical event that signals the litigation landscape for the CPT Hip System is about to fundamentally change. If you or someone you love received a Zimmer Biomet CPT Hip System implant and experienced a fracture, revision surgery, or chronic pain, understanding where this litigation stands right now could be the most important step you take.
What Is the Zimmer Biomet CPT Hip System and Why Was It Recalled?
The Zimmer Biomet CPT Hip System Femoral Stem with a 12/14 Neck Taper is a cobalt-chromium alloy hip replacement device that was widely implanted in patients undergoing total hip arthroplasty. Hip replacement is the single most common elective surgery performed in the United States, with more than 450,000 procedures performed annually, according to the CDC. Given those numbers, even a small percentage of defective implants translates into tens of thousands of patients at risk.
On July 2, 2024, Zimmer Biomet issued a voluntary recall of the CPT Hip System Femoral Stem 12/14 Neck Taper, citing an elevated risk of postoperative periprosthetic femoral fracture (PFF). The recall was logged in the FDA’s enforcement database and covered devices that had already been implanted in patients across the country. Critically, while Zimmer Biomet phased out sales of the device by December 2024, the implanted devices remain inside tens of thousands of patients whose bodies continue to carry the same fracture risk that prompted the recall in the first place.
Following the recall, Zimmer Biomet issued a Dear Surgeon letter recommending that healthcare providers use alternative devices where clinically feasible. The company’s own communication to surgeons acknowledged the fracture risk — a fact that plaintiffs’ attorneys are now citing as evidence that Zimmer Biomet had internal knowledge of the danger before patients were adequately warned.
The Science Behind the Fracture Risk: What Studies Show
The central scientific claim in every Zimmer Biomet CPT Hip lawsuit filed in 2026 is rooted in a troubling materials comparison. The CPT Hip System is constructed from a cobalt-chromium alloy, and studies cited by both the FDA and the UK Medicines and Healthcare products Regulatory Agency (MHRA) found that patients implanted with this device face a 1.4% periprosthetic femoral fracture rate. For context, comparable hip systems made from stainless steel carry a fracture rate of only 0.6% to 1.0%. That means patients with the CPT device face roughly twice the fracture risk of patients who received functionally similar devices made from a different material.
The UK MHRA’s Device Safety Information notice (DSI/2024/007) specifically identified the cobalt-chromium alloy composition as the material driver of this elevated risk. The FDA’s September 17, 2024 Medical Device Safety Communication reinforced this finding and warned healthcare providers to consider alternatives where available. This dual-regulator confirmation — from both U.S. and UK authorities — gives plaintiffs a powerful foundation for establishing that the device was unreasonably dangerous and that Zimmer Biomet knew or should have known about the risk.
| Data Point | CPT Hip System (Cobalt-Chromium) | Comparable Stainless-Steel Devices | Source |
|---|---|---|---|
| Periprosthetic Femoral Fracture Rate | 1.4% | 0.6%–1.0% | FDA Medical Device Safety Communications |
| Recall Issued | July 2, 2024 | N/A | FDA Enforcement Database |
| FDA Safety Communication | September 17, 2024 | N/A | FDA MDSC September 2024 |
| Sales Discontinued | December 2024 | N/A | Zimmer Biomet / FDA Database |
| Material Flagged as Risk Factor | Cobalt-Chromium Alloy | Stainless Steel | UK MHRA DSI/2024/007; FDA |
| Hip Replacements Performed Annually (U.S.) | 450,000+ | CDC National Health Statistics | |
Injuries Linked to the CPT Hip System: What Patients Experienced
The Zimmer Biomet CPT Hip lawsuit claims being filed in 2026 center on a specific cluster of serious, life-altering injuries. Understanding these injuries matters both for determining whether you qualify to file and for understanding what damages may be recoverable. When you use a medical malpractice calculator to estimate compensation for a defective medical device injury, the nature and severity of the harm is one of the most significant inputs.
The primary injuries alleged in CPT Hip System lawsuits include:
- Periprosthetic Femoral Fracture (PFF): A fracture of the femur bone around or near the hip implant. This is the defining injury in the CPT recall and can occur spontaneously or with minimal trauma. PFF is a serious orthopedic emergency requiring immediate hospitalization.
- Revision Surgery: Many fracture victims require complete surgical removal and replacement of the implant — a procedure that is significantly more complex and dangerous than the original hip replacement. Revision surgeries carry their own elevated complication profiles, including infection, nerve damage, and prolonged recovery.
- Permanent Disability: Some patients who suffer PFF and undergo revision surgery never regain full mobility, resulting in permanent physical limitations that affect their ability to work, care for themselves, or maintain their quality of life.
- Chronic Hip and Thigh Pain: Patients report ongoing, debilitating pain that persists even after treatment, significantly reducing daily function.
- Lost Wages and Earning Capacity: Extended recovery from fractures and revision surgeries often means weeks or months away from work, and in severe cases, permanent loss of earning capacity.
Who Qualifies to File a Zimmer Biomet CPT Hip Lawsuit in 2026?
Not everyone who received a Zimmer Biomet CPT Hip System implant automatically qualifies for a lawsuit, but the pool of potential claimants is significant. Lawyers actively accepting cases in 2026 are generally evaluating candidates based on the following criteria:
- Received a Zimmer Biomet CPT Hip System Femoral Stem with 12/14 Neck Taper implant — confirmed through surgical records or implant identification cards.
- Experienced a qualifying injury — specifically periprosthetic femoral fracture, required revision surgery, or suffered documented chronic pain or disability linked to device failure.
- Injury occurred or was discovered within the applicable statute of limitations — typically two to three years from the date of injury or the date a patient reasonably discovered the injury was linked to the device. Because the recall was issued in July 2024, many patients harmed in 2024 are still within the filing window in 2026.
- Not previously settled — patients who have not already resolved a claim related to this specific device or injury.
Statute of limitations rules vary significantly by state, and under the discovery rule recognized in most U.S. jurisdictions, the clock typically begins when a patient knew or reasonably should have known that their injury was connected to the implant — not necessarily the date of surgery. This nuance is critically important for patients who experienced fractures or complications but did not immediately connect them to a device defect.
The Pre-MDL Filing Window: Why July 2026 Is a Pivotal Moment
As of July 2026, the Zimmer Biomet CPT Hip lawsuit litigation has not yet been consolidated into a multidistrict litigation (MDL) proceeding. The existing Zimmer Biomet MDL 2859, currently pending in the Southern District of New York before Judge Crotty, covers only two residual cases from earlier M/L Taper litigation — it does not include CPT Hip System cases. Individual lawsuits are instead being filed in state and federal courts across all 50 states, creating a fragmented but active litigation landscape.
This week’s July 30, 2026 JPML hearing session in Asheville is significant. While the Zimmer Biomet CPT Hip lawsuit MDL petition has not yet been formally decided, the JPML’s active docket — which this week includes MDL motions for Nevro SCS and Abbott SCS cases — signals that the panel is in active consolidation mode. Legal experts widely anticipate that if CPT Hip System case volume continues to grow, an MDL petition will follow. You can review the JPML’s official docket and hearing schedule for real-time updates on pending consolidation motions.
The pre-MDL phase carries distinct strategic advantages for early filers. Plaintiffs who file before MDL consolidation may have more control over venue selection, discovery timelines, and case positioning. Historical benchmarks from similar mass tort litigation are instructive: the prior Zimmer Durom Cup MDL resulted in a base settlement of approximately $175,000 per hip, with the overall fund totaling $314 million. The DePuy ASR hip implant MDL — widely considered the most comparable litigation — settled for $2.5 billion, with individual claimants averaging approximately $250,000 per claim. These figures are not guarantees of what any individual may recover in the Zimmer Biomet CPT Hip lawsuit litigation, but they provide meaningful context for understanding the scale of similar defective hip implant cases. For an individualized sense of what your claim may be worth, a personal injury settlement calculator can help you assess key damage categories before speaking with an attorney.
Under products liability law as defined by Cornell Law School’s Legal Information Institute, manufacturers like Zimmer Biomet can be held liable under theories of design defect, manufacturing defect, and failure to warn. All three theories are potentially available to CPT Hip System plaintiffs, given that the cobalt-chromium material design has been identified as the root cause of elevated fracture risk, and given the gap between the July 2024 recall and the December 2024 sales discontinuation during which devices continued to be implanted.
Frequently Asked Questions About the Zimmer Biomet CPT Hip Lawsuit
What is the Zimmer Biomet CPT Hip System recall about?
Zimmer Biomet voluntarily recalled the CPT Hip System Femoral Stem 12/14 Neck Taper on July 2, 2024, because studies showed the cobalt-chromium alloy device caused periprosthetic femoral fractures at a rate of 1.4% — roughly twice the 0.6%–1.0% rate seen in comparable stainless-steel devices. The FDA issued a Medical Device Safety Communication on September 17, 2024 warning providers to use alternatives. Sales of the device were discontinued by December 2024, but implanted devices remain in tens of thousands of patients.
Can I still file a Zimmer Biomet CPT Hip lawsuit in 2026?
Yes. Attorneys across all 50 states are actively accepting new CPT Hip System cases in 2026. The statute of limitations for most patients harmed by the device — particularly those who experienced fractures or underwent revision surgery after the July 2024 recall — is still open in most states. The discovery rule means the clock typically runs from when you knew or should have known the injury was linked to the device, not from your original surgery date. Consulting an attorney promptly is strongly recommended because deadlines vary by state.
Has an MDL been formed for the Zimmer Biomet CPT Hip System?
As of July 2026, no MDL has been formed specifically for CPT Hip System cases. The existing Zimmer Biomet MDL 2859 in the Southern District of New York covers only residual M/L Taper cases and does not include CPT claims. Individual lawsuits are being filed in state and federal courts across the country. The JPML held its July 30, 2026 Asheville hearing session this week, and legal experts expect an MDL consolidation petition to be filed if case volume continues to grow.
What injuries qualify for a CPT Hip System lawsuit?
The primary qualifying injuries include periprosthetic femoral fracture (PFF) — a fracture of the thigh bone around the implant — as well as the need for revision surgery to remove and replace the device, permanent disability, chronic hip or thigh pain, and documented financial losses such as lost wages or loss of earning capacity. Patients who experienced these complications after receiving the Zimmer Biomet CPT Hip System Femoral Stem with 12/14 Neck Taper should discuss their specific circumstances with a qualified attorney.
How much could a Zimmer Biomet CPT Hip lawsuit be worth?
Individual settlement values in defective hip implant litigation have varied widely depending on injury severity, age, employment impact, and jurisdiction. For historical context, the earlier Zimmer Durom Cup MDL produced a base award of approximately $175,000 per hip within a $314 million total fund, while the DePuy ASR hip MDL averaged approximately $250,000 per claimant in a $2.5 billion settlement. These figures are not predictive of any individual outcome in the CPT Hip System litigation, and actual recoveries will depend on the specific facts of each case. No settlement has been announced in the CPT Hip litigation as of July 2026.
This content is provided for informational purposes only and does not constitute legal advice; consult a licensed attorney in your jurisdiction for guidance on your specific situation.
Related reading: Medtronic $88 Million Covidien Hernia Mesh Verdict: What 2026 Bellwether Trial Means For Pending Claims
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.